Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Cassava Sciences, Inc.    SAVA

CASSAVA SCIENCES, INC.

(SAVA)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/22/2021 01/25/2021 01/26/2021 01/27/2021 01/28/2021 Date
12.87(c) 15.68(c) 19.43(c) 19.75(c) 19.95 Last
2 994 814 4 256 649 7 685 455 7 070 231 1 109 594 Volume
+6.54% +21.83% +23.92% +1.65% +1.01% Change
More quotes
Financials (USD)
Sales 2020 - - -
Net income 2020 -5,27 M - -
Net Debt 2020 - - -
P/E ratio 2020 -98,8x
Yield 2020 -
Sales 2021 16,7 M - -
Net income 2021 5,35 M - -
Net Debt 2021 - - -
P/E ratio 2021 112x
Yield 2021 -
Capitalization 690 M 690 M -
Capi. / Sales 2020 -
Capi. / Sales 2021 41,4x
Nbr of Employees 9
Free-Float 91,8%
More Financials
Company
Cassava Sciences, Inc., formerly Pain Therapeutics, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing drug for the treatment of nervous system disorders. The Company is ocused on the early detection and treatment of neurodegenerative diseases, such as Alzheimer’s. Its drug candidate, PTI-125, is a small molecule that targets an altered form of a scaffolding protein called... 
More about the company
Notations Surperformance© of Cassava Sciences, Inc.
Trading Rating : Investor Rating : -
More Ratings
All news about CASSAVA SCIENCES, INC.
01/06CASSAVA SCIENCES INC : Change in Directors or Principal Officers, Regulation FD ..
AQ
01/04Cassava Sciences Appoints Dr. James Kupiec as Chief Clinical Development Offi..
GL
2020CASSAVA SCIENCES INC : Amendments to Articles of Inc. or Bylaws; Change in Fisca..
AQ
2020CASSAVA SCIENCES : USAN Modifies Lead Drug Candidate's Chemical Name to 'Simufil..
AQ
2020Cassava Sciences Says Lead Drug Candidate's Chemical Name Changed to 'Simufil..
MT
2020CASSAVA SCIENCES : USAN Modifies Lead Drug Candidate's Chemical Name to ‘S..
AQ
2020USAN Modifies Lead Drug Candidate's Chemical Name to ‘Simufilam'
GL
2020CASSAVA SCIENCES : Announces Pricing of $75 Million Public Offering of Common St..
AQ
2020CASSAVA SCIENCES INC : Entry into a Material Definitive Agreement, Other Events,..
AQ
2020AFTER HOURS WATCH LIST SCORECARD : Urov, ftch, sava
MT
2020MIDDAY REPORT : Wall Street Firmer After Choppy Trading Week
MT
2020Cassava Sciences Prices Public Offering of 9.4 Million Shares at Discount; Sh..
MT
2020Wall Street Set for Gains Following Upbeat Quarterly Earnings From Cisco, Dis..
MT
2020CASSAVA SCIENCES : Announces Pricing of $75 Million Public Offering of Common St..
AQ
2020Cassava Sciences Announces Pricing of $75 Million Public Offering of Common S..
GL
More news
News in other languages on CASSAVA SCIENCES, INC.

- No features available -

More news
Chart CASSAVA SCIENCES, INC.
Duration : Period :
Cassava Sciences, Inc. Technical Analysis Chart | SAVA | US14817C1071 | MarketScreener
Technical analysis trends CASSAVA SCIENCES, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Average target price 19,33 $
Last Close Price 19,75 $
Spread / Highest target 21,5%
Spread / Average Target -2,11%
Spread / Lowest Target -29,1%
EPS Revisions
Managers and Directors
NameTitle
Remi Barbier Chairman, President & Chief Executive Officer
Nadav Friedmann Director, Chief Operating & Medical Officer
Eric J. Schoen Chief Financial Officer
James W. Kupiec Chief Clinical Development Officer
Robert Z. Gussin Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
CASSAVA SCIENCES, INC.189.59%690
GILEAD SCIENCES, INC.12.39%82 081
WUXI APPTEC CO., LTD.36.65%63 102
VERTEX PHARMACEUTICALS-4.69%58 574
REGENERON PHARMACEUTICALS6.72%54 415
BEIGENE, LTD.24.12%29 244